1. Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome.
- Author
-
Wagner DG, Gatalica Z, Lynch HT, Kohl S, Johansson SL, and Lele SM
- Subjects
- Adenocarcinoma genetics, Aged, 80 and over, Carcinoma genetics, Carcinoma pathology, Carcinoma, Neuroendocrine genetics, Carcinoma, Small Cell genetics, Carcinoma, Small Cell pathology, Humans, Immunohistochemistry, Lynch Syndrome II genetics, Male, Microsatellite Instability, MutS Homolog 2 Protein genetics, Neoplasms, Multiple Primary genetics, Neoplasms, Second Primary pathology, Prostatic Intraepithelial Neoplasia genetics, Prostatic Intraepithelial Neoplasia pathology, Prostatic Neoplasms genetics, Ureteral Neoplasms genetics, Ureteral Neoplasms pathology, Adenocarcinoma pathology, Carcinoma, Neuroendocrine pathology, Lynch Syndrome II pathology, Neoplasms, Multiple Primary pathology, Prostatic Neoplasms pathology
- Abstract
Lynch syndrome is an autosomal-dominant cancer syndrome that can be identified with microsatellite instability molecular tests or immunohistochemical stains on pathologic material from patients who meet the Amsterdam Criteria II. The development of prostatic carcinoma in situ or invasive small cell carcinoma (SCC) of the prostate has not been previously reported in a patient with this syndrome. In this report, an 87-year-old White man with the Lynch syndrome had a prostate biopsy that revealed a mixed high-grade conventional adenocarcinoma and SCC of the prostate with high-grade prostatic intraepithelial neoplasia of the small cell neuroendocrine-type (HGPIN-NE), all showing MSH2 microsatellite instability and loss of MSH2 expression, a finding not previously published. These findings suggest that HGPIN-NE is a precursor of invasive SCC and also that prostatic SCC can develop in a patient with the Lynch syndrome.
- Published
- 2010
- Full Text
- View/download PDF